Overview

The Role of Orexin in Human Panic Disorder

Status:
Completed

Trial end date:
2020-03-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide some information (pilot data) about whether the study drug, suvorexant, (1) affects levels of orexin in people with panic disorder, and (2) is associated with decreased panic symptoms in response to a carbon dioxide (CO2) challenge.

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Francisco

Treatments:

Suvorexant